
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6093052/publications.pdf Version: 2024-02-01



INMES | MOHIED

#	Article	IF	CITATIONS
1	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
2	The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research, 2004, 10, 440-448.	7.0	629
3	Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4653-4657.	7.0	457
4	Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells. Molecular Endocrinology, 1997, 11, 450-459.	3.7	306
5	NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 620-623.	4.9	236
6	The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases. Advances in Urology, 2012, 2012, 1-18.	1.3	225
7	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8438-8443.	7.1	223
8	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	4.9	208
9	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European Urology, 2015, 67, 53-60.	1.9	205
10	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. Cancer Research, 2005, 65, 10514-10523.	0.9	186
11	Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. European Urology, 2017, 71, 183-192.	1.9	171
12	Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4365-4371.	7.0	166
13	Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer. Cancer Research, 2011, 71, 1486-1496.	0.9	135
14	Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer. Journal of Urology, 2003, 170, 1817-1821.	0.4	131
15	Racial Differences in Androgen Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. Journal of Urology, 2003, 170, 990-993.	0.4	129
16	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate, 2006, 66, 1292-1301.	2.3	129
17	Breast Cancer Resistance Protein–Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem Cells. Cancer Research, 2005, 65, 6640-6650.	0.9	119
18	Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP. Molecular Cancer Research, 2009, 7, 523-535.	3.4	112

#	Article	IF	CITATIONS
19	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	12.8	96
20	5αâ€reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate, 2011, 71, 1033-1046.	2.3	93
21	Castration-Recurrent Prostate Cancer Is Not Androgen-Independent. Advances in Experimental Medicine and Biology, 2008, 617, 223-234.	1.6	90
22	In vitro high resolution1h-spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magnetic Resonance in Medicine, 1993, 29, 285-291.	3.0	79
23	Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation. Cancer Research, 2007, 67, 9294-9303.	0.9	78
24	Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells. Cancer Research, 2006, 66, 5121-5129.	0.9	73
25	Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft. American Journal of Pathology, 2002, 160, 219-226.	3.8	70
26	Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone. Clinical Cancer Research, 2011, 17, 5844-5849.	7.0	65
27	Immunohistochemistry of the Androgen Receptor in Human Benign and Malignant Prostate Tissue. Journal of Urology, 1993, 149, 1015-1019.	0.4	64
28	Lipid degradation promotes prostate cancer cell survival. Oncotarget, 2017, 8, 38264-38275.	1.8	64
29	The North Carolina–Louisiana Prostate Cancer Project (PCaP): Methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate, 2006, 66, 1162-1176.	2.3	63
30	Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 2002, 51, 247-255.	2.3	62
31	Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft*. Endocrinology, 1999, 140, 2372-2381.	2.8	57
32	Expression of Annexin I, II and VII Proteins in Androgen Stimulated and Recurrent Prostate Cancer. Journal of Urology, 2004, 171, 916-920.	0.4	56
33	Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy. Journal of Urology, 2009, 181, 621-626.	0.4	54
34	Collagen Cross-Link Metabolites in Urine as Markers of Bone Metastases in Prostatic Carcinoma. Journal of Urology, 1994, 151, 909-913.	0.4	53
35	RACIAL DIFFERENCES IN PROSTATE ANDROGEN LEVELS IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 171, 2277-2280.	0.4	49
36	Surgical Competency for Urethrovesical Anastomosis During Robot-assisted Radical Prostatectomy: Development and Validation of the Robotic Anastomosis Competency Evaluation. Urology, 2015, 85, 27-32.	1.0	49

#	Article	IF	CITATIONS
37	Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 1992, 69, 511-519.	4.1	47
38	Overexpression of cyclin D1 is rare in human prostate carcinoma. , 1999, 38, 40-45.		46
39	Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. Journal of Urology, 2017, 197, 1237-1244.	0.4	46
40	Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular Signalling, 2010, 22, 1554-1561.	3.6	44
41	Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E263-E275.	3.5	44
42	High intratumoral CD8 <sup>+</sup> Tâ€cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate, 2021, 81, 20-28.	2.3	43
43	Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment. Urology, 2012, 79, 1197-1205.	1.0	40
44	Associations between patient–provider communication and socio-cultural factors in prostate cancer patients: A cross-sectional evaluation of racial differences. Patient Education and Counseling, 2014, 97, 339-346.	2.2	39
45	A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 357-372.	4.7	36
46	5αâ€reductase type 3 enzyme in benign and malignant prostate. Prostate, 2014, 74, 235-249.	2.3	36
47	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 140.	7.4	36
48	Melanoma Antigen-A11 (MAGE-A11) Enhances Transcriptional Activity by Linking Androgen Receptor Dimers. Journal of Biological Chemistry, 2013, 288, 1939-1952.	3.4	33
49	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research, 2014, 20, 6269-6276.	7.0	32
50	Prevalence and predictors of probable depression in prostate cancer survivors. Cancer, 2019, 125, 3418-3427.	4.1	32
51	Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP. Annals of Epidemiology, 2019, 29, 16-22.e1.	1.9	32
52	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
53	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	1.9	32
54	Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis. Urology, 2016, 97, 124-129.	1.0	30

#	Article	IF	CITATIONS
55	Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry, 1999, 35, 2-10.	1.8	29
56	Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and and and and receptor signaling response to steroid 51±-reductase inhibitors. Prostate, 2013, 73, 1470-1482.	2.3	29
57	The essential role of methylthioadenosine phosphorylase in prostate cancer. Oncotarget, 2016, 7, 14380-14393.	1.8	29
58	Biology of Castration-Recurrent Prostate Cancer. Urologic Clinics of North America, 2012, 39, 435-452.	1.8	28
59	5â€Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. Journal of Pathology, 2022, 256, 427-441.	4.5	28
60	A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemporary Clinical Trials, 2014, 38, 198-203.	1.8	27
61	Atmospheric Pressure Photoionization Tandem Mass Spectrometry of Androgens in Prostate Cancer. Analytical Chemistry, 2010, 82, 6000-6007.	6.5	26
62	Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway. Journal of Proteome Research, 2018, 17, 2963-2977.	3.7	26
63	Receipt of National Comprehensive Cancer Network guidelineâ€concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer, 2013, 119, 2282-2290.	4.1	25
64	Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4). Organic and Biomolecular Chemistry, 2017, 15, 7623-7629.	2.8	24
65	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	5.1	24
66	Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate, 2003, 57, 24-31.	2.3	23
67	Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment. International Journal of Biological Sciences, 2014, 10, 596-601.	6.4	23
68	Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. Nutrition and Cancer, 2016, 68, 214-224.	2.0	23
69	Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. PLoS ONE, 2015, 10, e0125151.	2.5	22
70	Cytochrome <i>c</i> Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer. Cancer Research, 2019, 79, 1353-1368.	0.9	22
71	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	1.9	22
72	Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer. Translational Oncology, 2008, 1, 153-157.	3.7	21

#	Article	IF	CITATIONS
73	Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate, 2014, 74, 722-731.	2.3	21
74	Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1395-1401.	4.9	21
75	The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biology and Therapy, 2010, 9, 1033-1042.	3.4	20
76	Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. British Journal of Nutrition, 2016, 115, 68-74.	2.3	20
77	Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	3.0	20
78	The Thoc1 Ribonucleoprotein and Prostate Cancer Progression. Journal of the National Cancer Institute, 2014, 106, dju306-dju306.	6.3	19
79	Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate, 2016, 76, 1053-1066.	2.3	19
80	Antineoplastic Isoflavonoids Derived from Intermediate <i>ortho</i> â€Quinone Methides Generated from Mannich Bases. ChemMedChem, 2016, 11, 600-611.	3.2	19
81	Association among plasma 1,25(OH) 2 D, ratio of 1,25(OH) 2 D to 25(OH)D, and prostate cancer aggressiveness. Prostate, 2019, 79, 1117-1124.	2.3	19
82	Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer, 1994, 74, 2996-3001.	4.1	18
83	Phenotype-Specific CpG Island Methylation Events in a Murine Model of Prostate Cancer. Cancer Research, 2008, 68, 4173-4182.	0.9	18
84	Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents. Organic and Biomolecular Chemistry, 2015, 13, 11292-11301.	2.8	18
85	The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy. Current Drug Targets, 2013, 14, 420-440.	2.1	18
86	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina–Louisiana Prostate Cancer Project. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 670-677.	2.5	17
87	Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World Journal of Urology, 1997, 15, 364-368.	2.2	16
88	New Developments in the Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 653-657.	4.9	16
89	Concept and viability of androgen annihilation for advanced prostate cancer. Cancer, 2014, 120, 2628-2637.	4.1	16
90	Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robotâ€assisted radical cystectomy for bladder cancer. BJU International, 2017, 119, 879-884.	2.5	16

#	Article	IF	CITATIONS
91	Modelling attrition and nonparticipation in a longitudinal study of prostate cancer. BMC Medical Research Methodology, 2018, 18, 60.	3.1	16
92	Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft. Endocrinology, 1999, 140, 2372-2381.	2.8	16
93	Low Detectable Prostate Specific Antigen after Radical Prostatectomy—Treat or Watch?. Journal of Urology, 2014, 192, 1390-1396.	0.4	15
94	Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer. Prostate, 2016, 76, 715-721.	2.3	14
95	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer and Prostatic Diseases, 2019, 22, 309-316.	3.9	14
96	A four gene signature predictive of recurrent prostate cancer. Oncotarget, 2017, 8, 3430-3440.	1.8	14
97	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical Cancer Research, 2022, 28, 414-424.	7.0	14
98	Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. BioMedical Engineering OnLine, 2005, 4, 31.	2.7	13
99	Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate, 2007, 67, 1011-1018.	2.3	13
100	14-3-3η Amplifies Androgen Receptor Actions in Prostate Cancer. Clinical Cancer Research, 2009, 15, 7571-7581.	7.0	13
101	The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate, 2013, 73, 1483-1494.	2.3	13
102	Efficient synthesis of aurone Mannich bases and evaluation of their antineoplastic activity in PC-3 prostate cancer cells. Chemical Papers, 2018, 72, 2443-2456.	2.2	13
103	Men's Eating and Living ( MEAL ) study ( CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU International, 2018, 121, 534-539.	2.5	13
104	Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate, 2015, 75, 1419-1435.	2.3	12
105	The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaPâ€NC. Prostate, 2017, 77, 878-887.	2.3	12
106	Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status. Biomolecules, 2020, 10, 1393.	4.0	12
107	Patterns and predictors of selfâ€reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 2019, 8, 3648-3658.	2.8	11
108	A CD24â€p53 axis contributes to African American prostate cancer disparities. Prostate, 2020, 80, 609-618.	2.3	11

#	Article	IF	CITATIONS
109	Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget, 2018, 9, 11227-11242.	1.8	11
110	The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2016, 27, 1475-1485.	1.8	10
111	Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a longâ€ŧerm followâ€up study. Prostate, 2022, , .	2.3	10
112	Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram. Cancers, 2022, 14, 1644.	3.7	10
113	Comparison of ACINUS, caspaseâ€3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis. Prostate, 2009, 69, 1603-1610.	2.3	9
114	Mechanism of androgen receptor corepression by CKÎ <sup>2</sup> BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Molecular and Cellular Endocrinology, 2014, 382, 302-313.	3.2	9
115	Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line. Prostate, 2016, 76, 1067-1077.	2.3	9
116	Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer. Asian Journal of Urology, 2019, 6, 50-56.	1.2	9
117	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	3.9	9
118	Use of Abiraterone for Prostate Cancer. Journal of Urology, 2011, 185, 783-786.	0.4	8
119	Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. Prostate Cancer, 2015, 2015, 1-8.	0.6	8
120	Serumâ€free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate, 2018, 78, 213-221.	2.3	8
121	Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2018, 32, 730-736.	2.1	8
122	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	5.9	8
123	The Role of Motility Proteins and Metastasisâ€6uppressor Genes in Prostate Cancer Progression. Stem Cells, 1996, 14, 508-516.	3.2	7
124	Characterization of Prostate Cancer in a Functional Eunuch. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1054-1060.	4.9	7
125	Statin use, high cholesterol and prostate cancer progression; results from HCaPâ€NC. Prostate, 2018, 78, 857-864.	2.3	7
126	Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. , 2004, 26, 194-200.		7

#	Article	IF	CITATIONS
127	Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5â€elpha reductase inhibitor treated human benign prostate hyperplasia patients. Prostate, 2022, 82, 1378-1388.	2.3	7
128	A novel method for the analysis of the androgen receptor. Current Urology Reports, 2002, 3, 67-74.	2.2	6
129	Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer. PLoS ONE, 2012, 7, e30192.	2.5	6
130	Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate, 2017, 77, 1076-1081.	2.3	6
131	Understanding the Relationship between Environmental Arsenic and Prostate Cancer Aggressiveness among African-American and European-American Men in North Carolina. International Journal of Environmental Research and Public Health, 2020, 17, 8364.	2.6	6
132	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Prostate, 2021, 81, 223-230.	2.3	6
133	Prostate tumor–derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. JCl Insight, 2020, 5, .	5.0	6
134	Tobacco use and outcome in radical prostatectomy patients. Cancer Medicine, 2017, 6, 857-864.	2.8	5
135	A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer. American Journal of Clinical and Experimental Urology, 2018, 6, 101-106.	0.4	5
136	Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. Canadian Journal of Urology, 2019, 26, 34-37.	0.0	5
137	Flow cytometric assay of pinocytosis: Correlation with membrane ruffling and metastatic potential in the dunning R-3327 rat prostatic adenocarcinoma model. Cytometry, 1993, 14, 826-831.	1.8	4
138	Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue. Prostate, 2015, 75, 1910-1915.	2.3	4
139	Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 663-665.	4.9	4
140	A Direct Synthesis of 2â€(ωâ€Carboxyalkyl)isoflavones from <i>ortho</i> â€Hydroxylated Deoxybenzoins. European Journal of Organic Chemistry, 2018, 2018, 5460-5463.	2.4	4
141	Pictet–Spengler condensations using 4-(2-aminoethyl)coumarins. New Journal of Chemistry, 2020, 44, 13415-13429.	2.8	4
142	Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 990-999.	2.5	4
143	Unit Nonresponse in a Population-Based Study of Prostate Cancer. PLoS ONE, 2016, 11, e0168364.	2.5	4
144	Editorial: Treatment Issues in Clinically Localized Prostatic Carcinoma. Journal of Urology, 1995, 154, 1433-1434.	0.4	3

#	Article	IF	CITATIONS
145	Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 1061-1068.	0.4	3
146	The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2018, 29, 1143-1150.	1.8	3
147	Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 597.	1.9	2
148	Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate, 2018, 78, 1069-1076.	2.3	2
149	Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer. , 2009, , 553-568.		2
150	INTRACRINE SYNTHESIS OF ANDROGENS BY PROSTATE CANCER IN RESPONSE TO ANDROGEN DEPRIVATION THERAPY. , 2011, , 193-218.		2
151	Ten Years of Progress in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 136-140.	4.9	1
152	5α-Reductase Isozymes in Castration-Recurrent Prostate Cancer. , 2009, , 175-185.		1
153	Racial Differences in Prostate Cancer Mortality. , 2007, , 355-376.		1
154	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. American Journal of Clinical and Experimental Urology, 2014, 2, 121-6.	0.4	1
155	Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer Causes and Control, 2022, , .	1.8	1
156	Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). European Urology Focus, 2022, 8, 1607-1616.	3.1	1
157	Genetic instability assessed by sister chromatid exchange analysis in the dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential. Prostate, 1995, 26, 247-252.	2.3	0
158	IL-15 The androgen axis in recurrent prostate cancer. Japanese Journal of Urology, 2004, 95, 280.	0.1	0
159	Editorial Comment. Journal of Urology, 2010, 183, 1797-1797.	0.4	0
160	In honor of Dr. Donald S. Coffey – Prostate cancer biology and therapy. Asian Journal of Urology, 2019, 6, 1-2.	1.2	0
161	Whole grain and dietary fiber intake and prostate cancer aggressiveness by race. FASEB Journal, 2010, 24, 729.2.	0.5	0
162	Title is missing!. Japanese Journal of Urology, 2011, 102, 341.	0.1	0

#	Article	IF	CITATIONS
163	Living WCRF Recommendations associated with less Prostate Cancer Aggressiveness among African and Caucasian Americans. FASEB Journal, 2012, 26, 388.4.	0.5	0